title: Co-existence of Philadelphia chromosome positive acute megakaryoblastic and B-lymphoblastic mixed blast crisis of chronic myeloid leukemia with chronic lymphocytic leukemia.
abstract: In this study, we describe an extremely rare case of co-existence of a Philadelphia chromosome positive acute megakaryoblastic and B-lymphoblastic mixed blast crisis of chronic myeloid leukemia with chronic lymphocytic leukemia. A morphological, immunophenotypical and cytogenetic study has been performed to characterize the case and in order to identify the origin of two disorders. After the failure of the conventional therapy, the patient was treated with Imatinib with a complete hematological and cytogenetic response and a marked reduction of bone marrow fibrosis.
authors.affiliation: Chair of Hematology and BMT Unit, University of Parma, Via Gramsci 14, 43100 Parma, Italy. ematopr@unipr.it
authors.forename: Simona
authors.initials: S
authors.lastname: Colla
authors.forename: Gabriella
authors.initials: G
authors.lastname: Sammarelli
authors.forename: Monica
authors.initials: M
authors.lastname: Crugnola
authors.forename: Stefano
authors.initials: S
authors.lastname: Ascani
authors.forename: Elena
authors.initials: E
authors.lastname: Sabbatini
authors.forename: Sabrina
authors.initials: S
authors.lastname: Bonomini
authors.forename: Magda
authors.initials: M
authors.lastname: Hojden
authors.forename: Luisa
authors.initials: L
authors.lastname: Craviotto
authors.forename: Isabel
authors.initials: I
authors.lastname: De Celis
authors.forename: Francesca
authors.initials: F
authors.lastname: Morandi
authors.forename: Cecilia
authors.initials: C
authors.lastname: Caramatti
authors.forename: Vittorio
authors.initials: V
authors.lastname: Rizzoli
authors.forename: Nicola
authors.initials: N
authors.lastname: Giuliani
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001549:Benzamides; D001752:Blast Crisis / Q000235:genetics / Q000473:pathology; D002051:Burkitt Lymphoma / Q000235:genetics / Q000473:pathology; D003561:Cytarabine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D016130:Immunophenotyping; D007621:Karyotyping; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000235:genetics / Q000473:pathology; D007947:Leukemia, Megakaryoblastic, Acute / Q000235:genetics / Q000473:pathology; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000235:genetics / Q000473:pathology; D009378:Neoplasms, Multiple Primary / Q000235:genetics / Q000473:pathology; D010879:Piperazines / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D012074:Remission Induction
chemical_list: D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D003561:Cytarabine; D000068877:Imatinib Mesylate; D003630:Daunorubicin